Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy

Core Insights - Crispr Therapeutics AG (CRSP) is a market leader in transformative therapies utilizing CRISPR/Cas9 technology, having received FDA approval in December 2023 and EMA approval in February 2024 for its product Casgevy [1] Company Overview - Crispr Therapeutics AG was founded in 2013 and is headquartered in Zug, Switzerland [1] Investment Perspective - The investment philosophy emphasizes the importance of compounding, dividend reinvesting, and patient investing through various market conditions to achieve significant rewards [1] - The strategy includes a mix of steady accumulation of high-quality assets along with high-risk/high-reward opportunities and transformative technologies [1]